Código 300410 (Harmonized System 2012 by 6 digits)
2024: US$20.7M, Total Trade Exchange
2024: US$5.99M, International Sales
2024: US$14.7M, International Purchases
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure). On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure). In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were India (US$513M), Austria (US$366M), and Italy (US$340M). In the same year, the main importing countries for Medicaments Containing Streptomycins or Derivatives Thereof, Incl. in Compounds with Penicillins or Derivatives Thereof, in Measured Doses "Incl. the Transdermal Administration Systems" or put up for Retail (Exc. Contained therein as Active Ingredients only Penicillins or Derivatives Thereof with a Penicillanic Acid Structure) were United States (US$481M), Egypt (US$234M), and Germany (US$232M).